No Data
China Resources Pharmaceutical Group's (HKG:3320) Investors Will Be Pleased With Their Decent 43% Return Over the Last Three Years
CHINARES PHARMA: China Resources Sanjiu Medical & Pharmaceutical's net income attributable to shareholders for the year 2024 is 3.369 billion yuan, an increase of 18.1% year-on-year.
CHINARES PHARMA (03320) announced that its subsidiary, China Resources Sanjiu Medical & Pharmaceutical (000999.SZ), achieved a total operating income of 27.617 billion yuan for the year ending December 31, 2024, an increase of 11.63% year-on-year; the Net income attributable to the shareholders of the listed company was 3.369 billion yuan, an increase of 18.1% year-on-year; basic earnings per share were 2.63 yuan.
China Resources Pharmaceutical's Shenzhen Listed Subsidiary Records 18% Higher Net Attributable Profit for 2024
CHINARES PHARMA: ANNOUNCEMENTPRELIMINARY FINANCIAL INFORMATION OF CR SANJIUFOR THE YEAR ENDED 31 DECEMBER 2024
CHINARES PHARMA: ANNOUNCEMENTPRELIMINARY FINANCIAL INFORMATION OF KPCFOR THE YEAR ENDED 31 DECEMBER 2024
China Resources Boya Bio-pharmaceutical Group (300294.SZ): The controlling shareholder has increased their shareholding by a total of 1.01%.
On February 10, Gelonghui reported that China Resources Boya Bio-pharmaceutical Group (300294.SZ) announced that it recently received a notice from its controlling Shareholder regarding the implementation progress of the Shareholding plan. CHINARES PHARMA intends to cumulatively increase its shareholding of the company by 5.1065 million shares through the trading system of the Shenzhen Stock Exchange by centralized auction trading between November 8, 2024, and February 7, 2025, which accounts for 1.0127% of the company's total equity.
